Skip to content

Investigating the effect of melatonin supplementation in obesity

Investigating the effect of melatonin supplementation on plasma levels of ghrelin, 2-arachidonoylglycerol and hedonic eating intensity

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20080904001197N22
Enrollment
46
Registered
2023-06-21
Start date
2024-02-04
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity. Obesity, unspecified

Interventions

Intervention 1: Intervention group: Participants in this group will take a 5 mg melatonin tablet one hour before going to bed at night with enough water for 8 weeks. Intervention 2: Control group: Par

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
19 Years to 49 Years

Inclusion criteria

Inclusion criteria: Apparently healthy women volunteers Literate 19-49 years BMI=25-34.9 kg/m2 Having high hedonic eating intensity Unwillingness to diet Desire to use drugs or supplements to lose weight

Exclusion criteria

Exclusion criteria: Postmenopausal, pregnant or lactating women Recent weight loss or participation in weight loss programs Suffering from binge eating Current smokers Recent history of taking supplements affecting appetite (in the last 3 months) Women who, according to themselves, are suffering from substance abuse, alcohol addiction, certain diseases such as cancer, heart disease and diabetes Women who, according to themselves, have hypothyroidism and use medicine for this purpose Women who, according to themselves, use drugs that affect appetite, such as antidepressants, steroids, and contraceptives Having night shifts Having severe insomnia or thyroid disorders Using drugs that interfere with melatonin (anti-hypertensive drugs, anticonvulsant drugs, beta blockers, anticoagulant drugs, sedatives, antidepressants, oral contraceptive pill, corticosteroids) Melatonin supplementation intolerance during the study Using less than 90% melatonin supplements or placebo

Design outcomes

Primary

MeasureTime frame
Plasma level of acyl ghrelin. Timepoint: Before starting and at the end of the study. Method of measurement: ELISA.

Secondary

MeasureTime frame
Plasma level of 2-arachidonylglycerol. Timepoint: Before starting and at the end of the study. Method of measurement: ELISA.;Hedonic eating score. Timepoint: The first phase of the study and at the end of the study. Method of measurement: Power of food scale.;Total energy intake. Timepoint: Before the start of the study, after 4 weeks, and at the end of the study. Method of measurement: 3-day food recall.;Energy intake from macronutrients. Timepoint: Before the start of the study, after 4 weeks, and at the end of the study. Method of measurement: 3-day food recall.;Weight. Timepoint: Before the start of the study, after 4 weeks, and at the end of the study. Method of measurement: Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMalihe Karamizadeh

Tabriz University of Medical Sciences

malihekarami1370@gmail.com+98 41 3335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026